Form 4: Tevogen Bio Holdings Grants 300,000 Restricted Shares to Chief Scientific Officer

Tevogen Bio Holdings Inc. has granted 300,000 restricted shares to its Chief Scientific Officer, Neal Flomenberg, as part of its 2024 Omnibus Incentive Plan, with vesting commencing in 2030.

Summary

• Neal Flomenberg, Chief Scientific Officer and Global R&D Lead of Tevogen Bio Holdings Inc. (TVGN), was granted 300,000 shares of common stock.
• The transaction date for this grant is June 27, 2025.
• The shares were granted at a price of $0, indicating a restricted stock award.
• Following this transaction, Neal Flomenberg beneficially owns 3,895,608 shares.
• The grant is part of the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The restricted stock will vest ratably in three equal annual installments.
• Vesting will commence on June 27, 2030.
• Vesting is contingent upon the reporting person remaining in service with the Issuer at the vesting dates.

Sentiment

Score: 6

Explanation: The grant of restricted stock to a key executive is generally positive for aligning interests, but the unusually long and deferred vesting schedule introduces uncertainty regarding its immediate motivational impact and long-term retention effectiveness.

Positives

• Granting of restricted stock to a key executive like the Chief Scientific Officer aligns management's interests with long-term shareholder value.
• The grant is part of an established 2024 Omnibus Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The vesting period is exceptionally long, commencing in 2030 and extending to 2032, which could be perceived as a very distant incentive.
• The grant date of June 27, 2025, and filing date of July 1, 2025, are in the future, which is unusual for a Form 4 reporting past transactions.

Risks

• Retention Risk: The very long vesting period (commencing in 2030) means the incentive for continued service is deferred, potentially impacting executive retention in the short to medium term.
• Performance Risk: The value of the restricted stock is tied to the future stock price, which is subject to market fluctuations and company performance over a very long horizon.

Future Outlook

The grant of restricted stock with a vesting schedule extending to 2032 indicates a long-term strategic outlook for executive retention and alignment with future company performance.

Management Comments

• Neal Flomenberg is identified as the Chief Scientific Officer and Global R&D Lead.

Industry Context

Executive compensation, particularly through equity grants like restricted stock, is a common practice in the biotechnology and pharmaceutical industries to attract and retain key scientific and leadership talent. Long vesting periods are often used to ensure long-term commitment in R&D-intensive sectors where product development cycles are extended.

Comparison to Industry Standards

• The grant of restricted stock to a Chief Scientific Officer is standard practice in the biotech industry for executive compensation.
• The vesting period commencing in 2030 and extending over three years is unusually long compared to typical industry standards, which often see vesting periods of 3-5 years starting from the grant date, not 5 years after the grant date.
• For example, many biotech companies like Moderna or BioNTech typically have 4-year vesting schedules for equity grants, often with a one-year cliff followed by monthly or quarterly vesting. Tevogen's 5-year deferral before vesting begins is a notable deviation.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Scientific Officer's long-term interests with shareholder value, but also represents potential future dilution upon vesting.
• Employees: May signal the company's commitment to retaining key talent, but the long vesting period might be viewed differently by other employees.

Next Steps

• The restricted stock will vest in three equal annual installments commencing on June 27, 2030.

Key Dates

Keywords

Tevogen Bio Holdings Inc., TVGN, Neal Flomenberg, Chief Scientific Officer, Restricted Stock Grant, SEC Form 4, Insider Ownership, Executive Compensation, Omnibus Incentive Plan, Biotechnology, Pharmaceuticals